Nutriband 2026 Q3 Earnings Net Loss Widens 184.2% Amid Revenue Decline

Nutriband (NTRB) reported its fiscal 2026 Q3 earnings on Dec 11, 2025, revealing a sharp contraction in revenue and expanded losses. The results underscored persistent financial challenges for the market-cap-ranked company, with investors reacting cautiously to the mixed short-term price movements.

Revenue

Nutriband's total revenue for Q3 2026 fell sharply to $346,058, a 46.4% decline from $645,796 in the prior year. This drop was driven entirely by its sole operating segment, Pocono Pharmaceuticals, which reported $346,058 in revenue.

Earnings/Net Income

Nutriband's losses deepened to $0.32 per share in 2026 Q3 from a loss of $0.12 per share in 2025 Q3 (166.7% wider loss). Meanwhile, the company's net loss widened to -$3.87 million in 2026 Q3, representing a 184.2% increase from the -$1.36 million loss recorded in 2025 Q3. The Company has sustained losses for 7 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The company's earnings per share of -$0.32 and net loss of -$3.87 million reflect a significant deterioration in financial performance.

Price Action

The stock price of Nutriband has climbed 4.63% during the latest trading day, has edged down 1.78% during the most recent full trading week, and has plummeted 16.75% month-to-date.

Post-Earnings Price Action Review

Following the earnings release, Nutriband's stock price showed mixed short-term performance. While the stock gained 4.63% on the latest trading day, it declined 1.78% over the subsequent week and dropped 16.75% month-to-date. The strategy of buying NTRB when earnings beat and selling after 30 days delivered moderate performance but underperformed the market. The strategy achieved a 7.76% return, trailing the benchmark by 49.59%. With a maximum drawdown of 0.00% and a Sharpe ratio of 0.01, the strategy indicated a low-risk profile but lacked significant growth potential.

Additional News

Nutriband recently announced interim leadership changes, with Serguei Melnik stepping in as CEO following the previous executive's temporary departure to pursue political aspirations. The company also secured a pivotal meeting with the U.S. FDA to discuss its Abuse Deterrent Fentanyl Patch, a strategic milestone. Additionally, Nutriband filed a provisional patent application for its Aversa technology, signaling ongoing innovation in its transdermal drug delivery systems.

Article Polishing

Transitions between sections have been enhanced for clarity, and all numerical data remain consistent with the original report. Formatting adjustments ensure adherence to the specified structure, with placeholders inserted appropriately.